4DFF
The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia
Summary for 4DFF
Entry DOI | 10.2210/pdb4dff/pdb |
Descriptor | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, MAGNESIUM ION, ZINC ION, ... (5 entities in total) |
Functional Keywords | zn binding, mg binding, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Cytoplasm: Q9Y233 |
Total number of polymer chains | 2 |
Total formula weight | 81487.75 |
Authors | Ho, G.D.,Seganish, W.M.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleichardt, C.,Hodgson, R. (deposition date: 2012-01-23, release date: 2012-03-14, Last modification date: 2012-04-04) |
Primary citation | Ho, G.D.,Michael Seganish, W.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleickardt, C.,Hodgson, R. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg.Med.Chem.Lett., 22:2585-2589, 2012 Cited by PubMed: 22377514DOI: 10.1016/j.bmcl.2012.01.113 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.11 Å) |
Structure validation
Download full validation report